Ordering Recommendation

Aids in the detection of nonclassical congenital adrenal hyperplasia in individuals presenting with hyperandrogenism.

Mnemonic

VIRIL PAN2

Methodology

Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Collect between 6-10 a.m.

Collect

Serum separator tube or green (sodium or lithium heparin). Also acceptable: Pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1.2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.7 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions
Remarks
Stability

Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months

Reference Interval

Test Number
Components
Reference Interval
  Testosterone by Mass Spec
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks) 59-125 5-16
Premature (31-35 weeks) 37-198 5-22
Newborn 75-400 20-64
1-5 months 14-363 Less than 20
6-24 months Less than 37 Less than 9
2-3 years Less than 15 Less than 20
4-5 years Less than 19 Less than 30
6-7 years Less than 13 Less than 7
8-9 years 2-8 1-11
10-11 years 2-165 3-32
12-13 years 3-619 6-50
14-15 years 31-733 6-52
16-17 years 158-826 9-58
18-39 years 300-1080 9-55
40-59 years 300-890 9-55
60 years and older 300-720 5-32
Premenopausal (18 years and older) Not Applicable 9-55
Postmenopausal Not Applicable 5-32
Tanner Stage I 2-15 2-17
Tanner Stage II 3-303 5-40
Tanner Stage III 10-851 10-63
Tanner Stage IV-V 162-847 11-62

  17-Hydroxyprogesterone, HPLC-MS/MS
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks) 124-841 124-841
Premature (29-35 weeks) 26-568 26-568
Full term Day 3 7-77 7-77
4 days-30 days Less than 200 7-106
1 month-2 months Less than 200 13-106
3 months-5 months 3-90 13-106
6 months-1 year Less than or equal to 148 Less than or equal to 148
2-3 years Less than or equal to 228 Less than or equal to 256
4-6 years Less than or equal to 208 Less than or equal to 299
7-9 years Less than or equal to 63 Less than or equal to 71
10-12 years Less than or equal to 79 Less than or equal to 129
13-15 years 9-140 9-208
16-17 years 24-192 Less than or equal to 178
18 years and older Less than 139 Less than 207
Follicular Not Applicable 15-70
Luteal Not Applicable 35-290
Tanner Stage I Less than or equal to 62 Less than or equal to 74
Tanner Stage II Less than or equal to 104 Less than or equal to 164
Tanner Stage III Less than or equal to 151 13-209
Tanner Stage IV-V 20-173 7-170

  Androstenedione by TMS
Age
Male (ng/mL)
Female (ng/mL)
Premature Infants (26-28 weeks Day 4) 0.92-2.82 0.92-2.82
Premature Infants (31-35 weeks Day 4) 0.80-4.46 0.80-4.46
Full Term Infants (1-7 days) 0.20-2.90 0.20-2.90
8-30 days 0.18-0.80 0.18-0.80
1-5 months 0.06-0.68 0.06-0.68
6-24 months 0.03-0.15 Less than 0.15
2-3 years Less than 0.11 Less than 0.16
4-5 years 0.02-0.17 0.02-0.21
6-7 years 0.01-0.29 0.02-0.28
8-9 years 0.03-0.30 0.04-0.42
10-11 years 0.07-0.39 0.09-1.23
12-13 years 0.10-0.64 0.24-1.73
14-15 years 0.18-0.94 0.39-2.00
16-17 years 0.30-1.13 0.35-2.12
18-39 years 0.33-1.34 0.26-2.14
40 years and older 0.23-0.89 0.13-0.82
Premenopausal Not Applicable 0.26-2.14
Postmenopausal Not Applicable 0.13-0.82
Tanner Stage I 0.04-0.32 0.05-0.51
Tanner Stage II 0.08-0.48 0.15-1.37
Tanner Stage III 0.14-0.87 0.37-2.24
Tanner Stage IV-V 0.27-1.07 0.35-2.05

  Dehydroepiandrosterone by TMS
Age Male (ng/mL) Female (ng/mL)
Premature Less than 40 Less than 40
0-1 days Less than 11 Less than 11
2-6 days Less than 8.7 Less than 8.7
7 days-1 month Less than 5.8 Less than 5.8
1-5 months Less than 2.9 Less than 2.9
6-24 months Less than 2.5 Less than 1.99
2-3 years Less than 0.63 Less than 0.85
4-5 years Less than 0.95 Less than 1.03
6-7 years 0.06-1.93 Less than 1.79
8-9 years 0.10-2.08 0.14-2.35
10-11 years 0.32-3.08 0.43-3.78
12-13 years 0.57-4.10 0.89-6.21
14-15 years 0.93-6.04 1.22-7.01
16-17 years 1.17-6.52 1.42-9.00
18-39 years 1.33-7.78 1.33-7.78
40 years and older 0.63-4.70 0.63-4.70
Postmenopausal Not Applicable 0.60-5.73
Tanner Stage I 0.11-2.37 0.14-2.76
Tanner Stage II 0.37-3.66 0.83-4.87
Tanner Stage III 0.75-5.24 1.08-7.56
Tanner Stage IV-V 1.22-6.73 1.24-7.88

Interpretive Data

Free or bioavailable testosterone measurements may provide supportive information.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

82157; 83498; 84403; 82626

Components

Component Test Code* Component Chart Name LOINC
0081058 Testosterone by Mass Spec 2986-8
0092332 17-Hydroxyprogesterone, HPLC-MS/MS 1668-3
2001639 Androstenedione by TMS 1854-9
2001641 Dehydroepiandrosterone by TMS 2193-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 17-Hydroxyprogesterone (Virilization Panel 2)
  • Androstenedione (Virilization Panel 2)
  • Dehydroepiandrosterone (Virilization Panel 2)
  • Testosterone (Virilization Panel 2)
Virilization Panel 2